Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | HTR1B | P28222 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13533242 | 1.00 | HTR1A (1.00) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| Hydrochloric Acid SCHEMBL7644692 | 0.99 | HTR1A (0.98) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| Mazapertine SCHEMBL7643633 | 0.99 | HTR1A (0.98) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| Mazapertine SCHEMBL6013382 | 0.95 | HTR1A (0.91) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| Mazapertine SCHEMBL1649526 | 0.95 | HTR1A (0.91) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| Mazapertine SCHEMBL120658 | 0.95 | HTR1A (0.91) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL9540919 | 0.90 | ADRA1D (0.82) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| Hydrochloric Acid SCHEMBL7647394 | 0.89 | HTR1A (0.80) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL9539641 | 0.89 | HTR1A (0.80) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL13533236 | 0.89 | HTR1A (0.80) | HTR1AADRA1DADRA1AADRA1BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 594 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| WO-2011126937-A1 | TARGETED INTRACELLULAR DELIVERY OF OLIGONUCLEOTIDES VIA CONJUGATION WITH SMALL MOLECULE LIGANDS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-10-13 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20100168085-A1 | Dopamine and agonists and antagonists thereof for modulation of suppressive activity of CD4+CD25+ regulatory T cells | YESA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE (IL) | 2010-07-01 | — | — | US | claimed |
| US-20090220611-A1 | Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same | FLAMEL TECHNOLOGIES, S.A. (FR) | 2009-09-03 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1626703-A2 | DOPAMINE AND AGONISTS AND ANTAGONISTS THEREOF FOR MODULATION OF SUPPRESSIVE ACTIVITY OF CD4+CD25+ REGULATORY T CELLS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2006-02-22 | — | — | EP | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1044023-B1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | LUITPOLD PHARM INC (US) | 2005-05-25 | — | — | EP | claimed |
| WO-2004103263-A2 | DOPAMINE AND AGONISTS AND ANTAGONISTS THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISEASES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-12-02 | — | — | WO | claimed |
| WO-2004103262-A2 | DOPAMINE AND AGONISTS AND ANTAGONISTS THEREOF FOR MODULATION OF SUPPRESSIVE ACTIVITY OF CD4+CD25+ REGULATORY T CELLS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-12-02 | — | — | WO | claimed |
| EP-0563345-B1 | NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES | MCNEILAB INC (US) | 2002-07-03 | — | — | EP | claimed |
| EP-0562049-A1 | NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES | MCNEILAB, INC. (US) | 1993-09-29 | — | — | EP | claimed |
| WO-1993004684-A1 | NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES | MCNEILAB, INC. (US) | 1993-03-18 | — | — | WO | claimed |